Cargando…
Temporality of body mass index, blood tests, comorbidities and medication use as early markers for pancreatic ductal adenocarcinoma (PDAC): a nested case–control study
OBJECTIVE: Prior studies identified clinical factors associated with increased risk of pancreatic ductal adenocarcinoma (PDAC). However, little is known regarding their time-varying nature, which could inform earlier diagnosis. This study assessed temporality of body mass index (BMI), blood-based ma...
Autores principales: | Tan, Pui San, Garriga, Cesar, Clift, Ashley, Liao, Weiqi, Patone, Martina, Coupland, Carol, Bashford-Rogers, Rachael, Sivakumar, Shivan, Hippisley-Cox, Julia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933161/ https://www.ncbi.nlm.nih.gov/pubmed/35760494 http://dx.doi.org/10.1136/gutjnl-2021-326522 |
Ejemplares similares
-
Identifying symptoms associated with diagnosis of pancreatic exocrine and neuroendocrine neoplasms: a nested case-control study of the UK primary care population
por: Liao, Weiqi, et al.
Publicado: (2021) -
IL-17A-producing CD8(+) T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts
por: Picard, Felix Simon Ruben, et al.
Publicado: (2023) -
Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma
por: Raj, Deepak, et al.
Publicado: (2019) -
Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages
por: Yu, Jun, et al.
Publicado: (2015) -
Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
por: Mayerle, Julia, et al.
Publicado: (2018)